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Background: Oxidative stress is implicated in increased vascular permeability associated with metabolic
disorders, but the underlying redox mechanism is poorly deﬁned. S-glutathionylation, a stable adduct of
glutathione with protein sulfhydryl, is a reversible oxidative modiﬁcation of protein and is emerging as
an important redox signaling paradigm in cardiovascular physiopathology. The present study determines
the role of protein S-glutathionylation in metabolic stress-induced endothelial cell permeability.
Methods and results: In endothelial cells isolated from patients with type-2 diabetes mellitus, protein
S-glutathionylation level was increased. This change was also observed in aortic endothelium in ApoE
deﬁcient (ApoE-/-) mice fed on Western diet. Metabolic stress-induced protein S-glutathionylation in
human aortic endothelial cells (HAEC) was positively correlated with elevated endothelial cell perme-
ability, as reﬂected by disassembly of cell-cell adherens junctions and cortical actin structures. These
impairments were reversed by adenoviral overexpression of a speciﬁc de-glutathionylation enzyme,
glutaredoxin-1 in cultured HAECs. Consistently, transgenic overexpression of human Glrx-1 in ApoE-/-
mice fed the Western diet attenuated endothelial protein S-glutathionylation, actin cytoskeletal dis-
organization, and vascular permeability in the aorta. Mechanistically, glutathionylation and inactivation
of Rac1, a small RhoGPase, were associated with endothelial hyperpermeability caused by metabolic
stress. Glutathionylation of Rac1 on cysteine 81 and 157 located adjacent to guanine nucleotide binding
site was required for the metabolic stress to inhibit Rac1 activity and promote endothelial hy-
perpermeability.
Conclusions: Glutathionylation and inactivation of Rac1 in endothelial cells represent a novel redox
mechanism of vascular barrier dysfunction associated with metabolic disorders.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. INTRODUCTION
Metabolic disorders such as obesity, diabetes mellitus, and
hyperlipidemia promote cardiovascular diseases, which are re-
sponsible for most of the morbidity, hospitalizations, and mortal-
ity in patients [1]. A common element in the complex pathogen-
esis of vascular complications is oxidative stress, which arises as
results of sustained overproduction of reactive oxygen species
(ROS) and impaired intrinsic antioxidant system, such asB.V. This is an open access article uglutathione (GSH) [2,3]. Protein S-glutathionylation is a reversible
oxidative modiﬁcation of protein cysteineyl residues by the addi-
tion of GSH, and represents an important mode of redox signal
transduction [4]. As a redox signaling switch, glutathionylation can
be efﬁciently and speciﬁcally removed by glutaredoxin-1 (Glrx-1)
via a thiol-disulﬁde exchange reaction in the presence of glu-
tathione, NADPH and glutathione reductase [5]. Glrx-1 has served
as an important tool to elucidate glutathionylation-mediated re-
dox signaling which appears to be an important regulator of var-
ious cellular processes [4,6,7]. Glutathionylation has been detected
in proteins involved in cellular response to diabetic conditions,
including protein kinase C [8]; NF-κB [9], protein tyrosine phos-
phatase 1B [10], and cAMP-dependent protein kinase [11].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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pates in metabolic stress-induced endothelial cell dysfunction.
Increased vascular permeability has been established as an
early characteristic of vascular dysfunction associated with meta-
bolic diseases [12–14]. It is thought to be one of initiate steps of
atherosclerosis by increasing lipoprotein entry and oxidation
within the sub-endothelial space, propagating endothelial cell
inﬂammation and favoring leukocyte transmigration [15,16]. Al-
though overproduction of oxidants and decrease in the ratio of
reduced to oxidized GSH (GSH/GSSG) have been linked to im-
paired endothelial cell barrier integrity [17,18], the redox-depen-
dent mechanisms remain elusive. Endothelial cell barrier function
is largely determined by the integrity of adherens junctions (AJs)
and actomyosin-based cell contractility, both of which are tightly
controlled by the dynamics of actin cytoskeletal architecture [19].
These dynamic processes are coordinately governed by Rho
GTPases including RhoA, Rac1 and Cdc42, whose activity is very
carefully controlled by their upstream regulatory proteins such as
guanine nucleotide exchange factors (GEFs), as well as by post-
transcriptional modiﬁcations including cysteinyl thiol oxidation
under physiological conditions [20–22]. Recently, accumulating
evidence showed that a defect in Rac1 activity and its mediated
cortical actin reorganization is mechanistically linked to peripheral
insulin resistance and neuronal complications associated with
obesity and diabetes. It is thus intriguing to investigate how glu-
tathionylation of Rho GTPases regulates endothelial barrier func-
tion and atherosclerosis under conditions of diabetes and
hyperlipidemia.
The present study is prompted by the observation of elevated
protein S-glutathionylation in endothelial cells isolated from pa-
tients with type 2 diabetes mellitus and hypercholesterolemia
mice. Our studies demonstrated that glutathionylation and in-
hibition of Rac1 may represent an important redox mechanism for
endothelial cell barrier failure caused by metabolic abnormalities.
Overexpression of Glrx-1 attenuates Western diet-induced protein
S-glutathionylation and preserves aortic endothelial barrier in-
tegrity. Collectively, these results suggest a causative role of pro-
tein S-glutathionylation in metabolic stress-induced endothelial
barrier dysfunction.2. Materials and methods
2.1. Animals
All animal experimental procedures were approved by the In-
stitutional Animal Care and Use Committee (IACUC) at Boston
University Medical Campus. Glrx-1 transgenic mice with human
Glrx-1 overexpression driven by the mouse β-actin promotor (a
kind gift from Dr. Y.S. Ho, Wayne State University, Detroit, MI)
were fully backcrossed onto a C57BL/6 background and crossed
with ApoE-deﬁcient mice (B.6 129P2) purchased from Jackson
Laboratory (Bar Harbor, ME). Global Glrx-1 transgenic /ApoE-/-
mice and WT littermates were fed a control (normal chow, ND:
4.5% fat, 0.02% cholesterol by weight), or a Western diet (WD: 21%
fat, 0.21% cholesterol by weight and 35% sucrose) purchased from
Research Diets Inc. (D12079B, New Brunswick, NJ) for two weeks
starting at 8 weeks of age. We use only male mice for experiments.
2.2. Immunoﬂuorescence histochemistry and atherosclerotic lesion
quantiﬁcation
To analyze glutathionylated proteins in aorta with im-
munohistochemistry, the arterial tree of mice was perfused with
ice-cold PBS containing NEM (10 mM) to alkylate the free protein
thiols [23]. The cross sections of aorta were incubated with NEM(10 mM) in PBS on ice for 15 min and ﬁxed with acetone for
15 min at 20 °C, followed by immunoﬂuorescence staining pro-
cedure described in online-only data supplement.
To analyze glutathionylated proteins and actin cytoskeleton
structures in aortic endothelium in vivo, aortas from ApoE-/-and
Glrx-1 TG on ApoE-/-mice fed WD for 2 weeks were perfused with
NEM buffer and 2% paraformaldehyde, sequentially. The dissected
ascending aorta and proximal arch segments were opened long-
itudinally and subjected to immunoﬂuorescence staining for actin
and glutathionylated proteins.
2.3. Human venous endothelial cell collection, immunostaining and
quantiﬁcation
We enrolled adults with type 2 diabetes mellitus deﬁned as
fasting serum glucose Z126 mg/dL or ongoing treatment for type
2 diabetes mellitus at Boston Medical Center and control in-
dividuals without diabetes mellitus deﬁned as fasting glucose
r100 mg/dL. All subjects were studied in the fasting state, and a
blood sample was taken for measurement of lipid levels and glu-
cose levels in the Boston Medical Center Clinical Laboratory. Per-
ipheral venous endothelial cell biopsy was performed as pre-
viously described [24]. The isolated ECs were co-immunostained
for glutathionylated proteins and Von Willebrand Factor (vWF) to
aid in endothelial cell identiﬁcation. Fluorescence intensity was
quantiﬁed in 20–30 cells from each subject. The detailed proce-
dure is described in online-only data supplement.
2.4. Cell culture and treatments
Human aortic endothelial cells (HAECs), purchased from Lonza
(Walkersville, MD), were treated for indicated period of time with
vehicle (5 mM glucose, 20 mM mannitol and fatty acid free BSA at
indicated concentrations in starvation medium supplemented
with 0.1% FBS) or high palmitate and high glucose at indicated
concentrations (HPHG). HAECs were incubated with an inhibitor of
Rac1, 100 μM NSC-23766 (Santa Cruz Biotech., Dallas, TX) for
30 mins, followed by HPHG treatments.
Transfection of siRNA was performed using siRNA transfection
reagent and medium according to the manufacture’s protocol from
Santa Cruz Biotechnology. HAECs were infected with adenoviruses
encoding LacZ (control) or human Glrx-1 (a generous gift from Dr.
Young J. Lee, the University of Pittsburgh) [6] for 24 h before fur-
ther treatments. Rac1-deﬁcent COS-7 cells were transiently
transfected with plasmids encoding Rac1 WT and mutants using
Lipofectamine 3000 according to the manufacturer’s instruction.
The detailed procedure is described in online-only data
supplement.
2.5. Generation of cysteine to serine Rac1 mutants
Single amino acid substitutions (Cys18S, Cys81S, and Cys157S)
of Rac1 were created using pGFP-Rac1WT as a template and the
QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent
Technologies, Santa Clara, CA). Primers were designed using the
QuickChange Primer Design program and are available upon re-
quest. All mutations were conﬁrmed by DNA sequencing (Gene-
wiz, Inc., South Plainﬁeld, NJ).
2.6. Rac1 knockdown by CRISPR/Cas-9 system
pSpCas9/sgRNA(BB)2A-Puro (PX459) V2.0 plasmid was used
to generate Cas9 endonuclease targeted to Rac1 gene in green
monkey kidney ﬁbroblast cells (COS-7) following the procedure
described in [25]. COS-7 cells transfected with sequence-veriﬁed
empty or Rac1 knockout CRISPR/Cas9 plasmids were harvested for
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detailed procedure is described in online-only data supplement.
2.7. Rho GTPases activation assays
Activation of RhoA, Rac1 and Cdc42 GTPases was determined in
HAECs lysates using pull-down assay kits purchased from Cyto-
keleton (Denver, CO).
2.8. Endothelial permeability measurement in vitro and in vivo
HAEC monolayers cultured onto Transwell culture inserts were
transfected with adenoviral LacZ (control) or Glrx-1, or with non-
targeting siRNA or Glrx-1 siRNA. Cells then were exposed to HPHG
at indicated concentrations followed by assay of FITC-dextran in-
ﬂux across the Transwell membrane described in online-only data
supplement.
To measure aortic permeability in vivo, 0.5% Evans Blue Dye
(EBD) in PBS containing 4% BSA at the dosage of 30 mg/Kg was
intravenously administrated to mice and allowed to circulate for
60 min before euthanasia. The extravasation of EBD-BSA into
aortic wall was assessed as described in online-only data
supplement.
2.9. Biotin-switch assay for labeling of reversible cysteine oxidation
in proteins extracted from HAECs and whole aortae
Total reversible cysteinyl thiols of proteins extracted from
HAECs were assessed as previously described in [26,27]. The de-
tailed procedure is described in online-only data supplement.
2.10. Analysis of glutathionylated Rac1 in COS-7 cells using bioti-
nylated GSH ethyl ester
Glutathionylation of Rac1 was accessed using biotinylation
method as previously described [28]. COS-7 cells loaded with
500 μM BioGEE were exposed to vehicle or HPHG as indicated.
Glutathionylated proteins in cleared cell lysates were enriched by
streptavidin magnetic beads, followed by Western blotting analy-
sis of Rac1 and β-actin. The detailed procedure is described in
online-only data supplement.
2.11. Quantitative real-time PCR
Total RNA isolated from the whole aorta using TRIzol™ reagent
(Invitrogen) was converted to cDNA serving as a template for PCR.
Quantitative PCR was conducted using inventory mouse (Mm)
gene-speciﬁc TaqMan™ Primers with StepOne™ real-time PCR
software (Applied Biosystems).
2.12. Statistical analysis
Statistical analysis was performed using Prism 6.0 (GraphPadFig. 1. Protein S-glutathionylation in endothelial cells is increased under conditions of
diabetic endothelial cells (ECs). A: Representative images of immunoﬂuorescence stainin
intensity of PrS-SG staining in ECs from diabetic subjects (n¼5) and control subjects (n¼
PrS-SG, and the ﬂuorescence density was measured and averaged. Data represent mean
Representative images showing the localization and levels of PrS-SG in the cross section
two weeks. Freshly prepared aortic tissue cross sections were incubated with 10 mM NEM
(red channel), CD31(EC marker, green channel) and α-actin (smooth muscle cell marke
yellow-boxed areas. Scale bars are 50 mm. D: Two-week WD feeding dramatically incr
represent mean7SEM (ND: n¼7; WD: n¼12). *po0.05, compared with ND group. E:
treated with vehicle (50 μM BSA, 5 mM D-glucose, 20 mMmannitol) or high levels of pal
Cells were then incubated with 10 mM NEM for 15 min to alkylate free protein thiols, a
antibody under nonreducing condition. The right panel is the image with short exposure
color in this ﬁgure legend, the reader is referred to the web version of this article.)Software). Means were compared between two groups by the
Mann-Whitney U test. Multiple comparisons were conducted with
1-way ANOVA followed by Dunnett test. A value of po0.05 was
considered statistically signiﬁcant. Analysis of ﬂuorescence in-
tensity of ECs from human subjects was conducted using a mixed
model. The average of intensity in arbitrary units obtained from 20
to 30 measurements per human subject was used as the depen-
dent variable, and sample types (control vs. DM) were used as the
independent variable adjusting for different batches of patient
cells, with a random effect for each to account for within-person
correlation.3. RESULTS
3.1. Protein S-glutathionylation is increased in endothelial cells un-
der conditions of diabetes and hypercholesterolemia
To gain insight into the clinical relevance of protein S-glu-
tathionylation (PrS-SG) to vascular endothelial cell dysfunction
associated with metabolic disorders, endothelial cells isolated
from patients with Type 2 diabetes mellitus and non-diabetic
control subjects were obtained and co-immunostained for PrS-SG
and Von Willebrand factor (vWF, endothelial cell marker). As
shown in Fig. 1A and B, the level of PrS-SG was signiﬁcantly in-
creased in diabetic endothelial cells. As Type 2 diabetes is usually
associated with hyperlipidemia, a major risk factor for cardiovas-
cular diseases [30], we next test whether in hypercholesteremic
mice the level of PrS-SG in the aorta is altered through comparing
PrS-SG staining density in cross sections of aortae from ApoE-/-
mice fed normal chow (ND) and Western diet (WD) for two weeks.
As shown in Fig. 1D and E, two-week WD feeding dramatically
increased the plasma levels of cholesterol, but not triglycerides. In
WD-fed ApoE-/- mice, the staining intensity of PrS-SG was dra-
matically higher in the aortic vessel wall than that in ND-fed
ApoE-/- mice. In a more detailed analysis (Fig. 1C), the intense
staining for PrS-SG was highly colocalized with CD31 positive
endothelial cells, but not in smooth muscle cells stained with α-
actin. The speciﬁcity of PrS-SG staining was veriﬁed by demon-
strating that immunoﬂuorescence signals in aortic specimens
were abolished by treatment with thiol reducing agent, dithio-
threitol (DTT) for cleaving protein disulﬁde bonds (Supplemental
Fig. 1). Also, we demonstrated in Fig. 1F and G that PrS-SG was
induced in cultured human aortic EC cells (HAECs) exposed to high
levels of palmitate and glucose, which mimics high circulating
levels of saturated free fatty acids (FFA) and glucose in vivo asso-
ciated with metabolic disorders. In vitro treatment of endothelial
cells with palmitate and/or high level of glucose have been well
documented to induce endothelial dysfunctions including oxida-
tive stress, inﬂammation, apoptosis, impaired eNOS signaling [31–
35]. These results obtained from human samples and experimental
models of metabolic disorders both in vivo and in vitro together
clearly indicate that PrS-SG is induced in endothelial cells underdiabetes and hypercholesteremia. Glutathionylated proteins (PrS-SG) is elevated in
g of PrS-SG in ECs isolated from diabetic and non-diabetic control subjects. B: The
5) was quantiﬁed. From each subject sample, 20–30cells were immunostained for
7SEM. *pr0.05. C: PrS-SG is elevated in aortic ECs in hypercholesterolemic mice.
s of aortae from ApoE-/- mice fed a normal chow (ND) and a Western diet (WD) for
to alkylate free thiols, ﬁxed with ice-cold acetone, and immunostained for PrS-SG
r, green channel). The ﬁrst and the third row shows high magniﬁcation views of
eased the plasma levels of cholesterol, but not triglycerides in AopE-/- mice. Data
PrS-SG is elevated in cultured HAECs exposed to diabetic conditions. HAECs were
mitate-BSA conjugate and high glucose (HPHG) at indicated concentrations for 24 h.
nd the cleared cell lysates underwent Western blotting analysis with the anti-GSH
. The β-actin blot serves as a loading control. (For interpretation of the references to
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nylation in the regulation of endothelial cell responses to meta-
bolic cues.
3.2. Overexpression of Glrx-1 reduces protein S-glutathionylation
and improves aortic endothelial barrier function in response to me-
tabolic stress in vitro
To test the hypothesis of that glutathionylation plays a role in
the redox regulation of endothelial barrier function, which has
long been recognized as an early phenotypic change associated
with metabolic disorders [12]. Genetic manipulation of Glrx-1
expression in endothelial cells was employed to control glu-
tathionylation level. As shown in Fig. 2A and B, adenoviral over-
expression of Glrx-1 efﬁciently inhibited PrS-SG induction in
HAECs challenged by HPHG. We next examined the impact of
HPHG treatment on HAEC permeability using a well-established
two-compartment chamber in vitro model as described. In con-
sidering the apoptotic effect of chronic exposure to HPHG on en-
dothelial cells [31,32], we chose to challenge HAECs with HPHG for
two hours after ensuring this condition could not stimulate robust
apoptotic signals (supplemental Fig. 2). HPHG treatment increased
the permeability of HAEC monolayer to ﬂuorescein-labeled dex-
tran in a dose-dependent manner (Fig. 2C). More importantly, The
HPHG-induced endothelial hyperpermeability was protected by
overexpression of Glrx-1 (Fig. 2D), and aggravated by siRNA-
mediated downregulation of Glrx-1 (Fig. 2E), supporting a critical
role of PrS-SG in metabolic stress-induced EC barrier regulation.
We next directly visualized and accessed the EC barrier integrity
and actin cytoskeletal structure through immunostaining of VE-
cadherin (a molecular marker of adhesion junctions) and F-actin in
HAECs under control and metabolic stress conditions. Consistently,
HPHG treatment induced disappearance of VE-Cadherin from
contact cell borders associated with intercellular gap formation,
which was prevented by overexpression of Glrx-1 (Fig. 2F and G).
As shown in Fig. 2H and I, under basal condition, overexpression of
Glrx-1 stimulated F-actin polymerization. HPHG challenge sig-
niﬁcantly increased the formation of stress ﬁbers in HAECs in-
fected with AdLacZ, but not in the cells overexpressing Glrx-1.
These results together suggest a protective role of Glrx-1 in me-
tabolic stress-induced barrier dysfunction.
3.3. Vascular permeability is attenuated in the aorta of transgenic
overexpression of Glrx-1 in ApoE-/- mice fed the Western diet-
To gain further insights into the role of protein S-glutathiony-
lation in vascular barrier dysfunction associated metabolic dis-
orders in vivo, human Glrx-1 transgenic mice were bred onto hy-
percholesteremic ApoE deﬁcient background (Glrx-1-TG/ApoE-/-)Fig. 2. Adenoviral overexpression of Glrx-1 attenuates metabolic stress-induced protein
abrogates HPHG-induced PrS-SG in ECs. HAECs were infected with an adenovirus express
with vehicle (25 μM BSA, 5 mM glucose, 20 mannitol) and HPHG (100 μM palmitate-BSA
immunostaining for PrS-SG (red channel) and Glrx-1 (green channel) with antibodies ag
yellow boxed areas. Green outlined cells overexpress Glrx-1. Fifteen randomly selecte
(n¼15). *pr0.05 between indicated groups. C: HPHG treatment increases endothelia
Transwell inserts were exposed to HPHG at indicated concentrations for 2 h, followed b
dextran passing across monolayers relative to the control group and represented as mea
compared with vehicle group. D-E: Adenoviral overexpression of Glrx-1 (D) protected
permeability. The expression of Glrx-1 in HAECs infected with adenovirus or siRNAs we
*po0.05 compared between indicated groups. F–I: Overexpression of Glrx-1 in HAECs p
challenge. Adenovirus-infected HAECs were exposed to vehicle (50 μM BSA, 5 mM glucos
2 h, followed by immunostaining for VE-Cadherin, a marker for cell-cell junctions (F,
ﬂuorescence-labeled phalloidin (H). The second and last column shows high magniﬁed
(VE-Cadherin staining density/total area of image ﬁeld)100/cell number), and F-actin s
independent experiments. Intercellular gaps were indicated by white arrows. Results re
interpretation of the references to color in this ﬁgure legend, the reader is referred to tafter verifying the expression of human Glrx-1 and increased en-
zymatic activity of Glrx-1 in endothelial cells from Glrx-1 TG mice
(Fig. 3A). Glrx-1-TG/ApoE-/- and their littermates (WT/ApoE-/-)
were fed ND or WD for two weeks when no signiﬁcant aortic
atherosclerotic plaques were observed. Consistently, two-week
WD diet increased the level of PrS-SG in cross-sections of the aorta
from WT mice, but to a much less extent in Glrx-1 TG mice
(Fig. 3B). En face co-immunostaining for PrS-SG and F-actin of
aortic endothelial cells at lesion-prone sites on the lesser curvature
of the aortic arch showed that overexpression of Glrx-1 attenuated
the formation of PrS-SG and preserved F-actin structure in aortic
endothelium in WD-fed ApoE-/- mice (Fig. 3C). Furthermore, Aortic
permeability was assayed by measuring permeation of BSA-con-
jugated Evans blue dye (EBD) into the vessel wall, a well-estab-
lished approach to access vascular permeability in vivo [36].
Compared with WD-fed WT/ApoE-/- mice, BSA-EBD leakage in the
aorta of Glrx-1 TG was signiﬁcantly decreased (Fig. 3D and E). Of
note, overexpression of Glrx-1 in ApoE-/- mice does not affect
plasma lipid proﬁles and fasting glucose level (Supplemental Ta-
ble 1). As the increased vascular permeability may result from EC
inﬂammatory responses to leukocyte transendothelial migration
and activation, we examined the expression of adhesion mole-
cules, VCAM-1 and ICAM-1, as well as the leukocyte chemoat-
tractant, MCP-1, in aortae of Glrx-1-TG/ApoE-/- and WT/Apo E -/-
mice on ND and WD. As shown in Fig. 3F, gene expression of
VCAM-1 and MCP-1 was elevated in aortae fromWD-fed mice, but
there were no statistically signiﬁcant differences between Glrx-1-
TG/ApoE-/- and their littermates. Consistent with a previous report,
aortic mRNA level of ICAM-1 was not increased in response to WD
[37]. Taken together, these data demonstrated an important role of
protein S-glutathionylation in regulating vascular barrier dys-
function associated with metabolic abnormalities in vivo.
3.4. Overexpression of Glrx-1 preserves the activity of small Rho
GTPase Rac1 in endothelial cells exposed to metabolic stress
Small Rho GTPases including RhoA and Rac1 are putative
master regulators of dynamic actin cytoskeleton arrangement and
are well recognized redox-sensitive signaling molecules as well
[20,22,38]. We thus tested their role in redox regulation of actin
cytoskeletal reorganization and barrier function.
To assess the effect of metabolic stress on the activities of Rho
GTPases in endothelial cells, we performed afﬁnity pull-down as-
says to detect the activity of RhoA, Rac1 and Cdc42 in HAECs ex-
posed to increasing concentrations of HPHG for two hours. The
data shown in Fig. 4A and B indicate that HPHG treatment dif-
ferentially regulated their activities. Speciﬁcally, HPHG challenge
activated RhoA but inhibited Rac1 activity dose-dependently. The
activity of Cdc42 determined from the same pull-down samplesS-glutathionylation and endothelial cell permeability. A–B: Overexpression of Glrx-1
ing human Glrx-1 or a control adenovirus (AdlacZ) for 24 h. Cells were then treated
conjugate, 25 mM glucose) in a serum-free medium for another 24 h, followed by
ainst GSH and Glrx-1, respectively. The ﬁrst row shows high magniﬁcation views of
d image ﬁelds from three independent experiments were used for quantiﬁcation
l cell permeability in a dose-dependent manner. HAEC monolayers cultured onto
y FITC-dextran inﬂux assay. Results are the normalized percentages of total FITC-
n 7 SD of three independent experiments, each performed in triplicates. *po0.05,
against, siRNA-mediated downregulation of Glrx-1(E) exacerbated HPHG-induced
re assessed by immunoblotting shown in the lower panels of D and E, respectively.
rotected cell-cell adherens junctions and actin cytoskeletal structures against HPHG
e, 20 mMmannitol) or HPHG (200 μM palmitate-BSA conjugate, 25 mM glucose) for
red channel), and Glrx-1 (F and H, green channel). F-actin was stained with red
views of yellow boxed areas. Junctional index (G) as a measure of barrier integrity
taining intensity (F) were measured in 15 randomly selected image ﬁelds from three
present mean7SEM (n¼15). *po0.05, compared between indicated groups. (For
he web version of this article.)
Fig. 3. Transgenic overexpression of human Glrx-1 in ApoE-/- mice attenuates hypercholesterolemia-induced protein S-glutathionylation and aortic barrier dysfunction
in vivo. A. ECs isolated from the lung of human Glrx-1 transgenic (hGlrx-1 TG) mice express human Glrx-1. B-C: hypercholesterolemia-induced PrS-SG is diminished in aortic
endothelium of hGlrx-1 TG mice, accompanied by preserved EC actin cytoskeletal structure. WT and hGlrx-1 TG mice on ApoE-/- background were fed ND or WD for
2 weeks. B: Representative immunoﬂuorescence images show PrS-SG staining in aortic cross-sections from WT and hGlrx-1 TG. Inserts are high magniﬁcation views of
yellow boxed areas. Scale bar is 50 mm. C: Representative en face confocal ﬂuorescence images of PrS-SG (red channel) and cytoskeletal organization (F-actin, green channel)
in aortic endothelium at the lesser curvature of aortic arch segments fromWT and hGlrx-1 TG mice. The second and last column show high magniﬁcation view of yellow box
areas. Scale bars are 20 mm. D–E: Hypercholesterolemia-induced aortic permeability is attenuated in hGlrx-1 TG mice. Aortic permeability in WT and hGlrx-1 TG mice on ND
and WD was assessed by BSA-Evans blue dye (BSA-EBD) conjugate permeation method. F: Representative photographs of BSA-EBD leakage in aortic arch segments of mice.
Scale bar is 200 mm. G: The permeated EBD in aortae was extracted, measured, and presented as means7SEM (WT: n¼5–9; hGlrx-1 TG: 5–10). *po0.05 between indicated
groups. H: Hypercholesterolemia-induced inﬂammatory genes including MCP1, VCAM1, and ICAM1, in aorta is not affected by overexpression of hGlrx-1. Bar graphs show
normalized mRNA level of inﬂammatory genes relative to ND group. Data are represented as mean7SEM. WT on ND (n¼5) and WD (n¼5). hGlrx-1 TG on ND (n¼5) and
WD (n¼7). *po0.05 vs. WT mice on ND group, † po0.05 vs. hGlrx-1 TG mice on ND group. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
Fig. 4. Overexpression of Glrx-1 preserves Rac1 activity in endothelial cells under conditions of metabolic stress. A–B: Effect of HPHG treatment on the activity of RhoA, Rac1,
and Cdc42 in HAECs. HAECs were exposed to HPHG at the indicated concentrations for 2 h, followed by activity assays for RhoA, Rac1, and Cdc42. A: Representative Western
blotting result for RhoA, Rac1, and Cdc42 in the GTP-bound form and 10% of total input. B: Bar graph shows the corresponding densitometric analysis of active RhoGTPases
(ratio of GTP-bound form over total GTPases) from three independent experiments. *po0.05 vs. vehicle group. C–F: Effect of PrS-SG induction on the activity of Rac1 and
RhoA in HAECs. HAECs exposed to 50 μM diamide (C and E, left panel), or 20 μg cell lysates incubated with a mixture of 1 mM GSSG/3 mM GSH on ice for 30 mins (C and E,
right panel), were subject to RhoA and Rac1 pull-down activity assays. D and F: The corresponding Densitometric analysis of blot data for the activity of Rac1 and RhoA,
respectively. *po0.05 vs. vehicle group. G–H: Effect of Glrx-1 overexpression on Rac1 activity in HAECs exposed to HPHG. HAECs were infected with an adenovirus
expressing hGlrx-1 or a control adenovirus (AdLacZ) for 24 h, followed by HPHG treatment (200 μM palmitate-BSA conjugate, 25 mM glucose) for 2 h. Cells were then subject
to Rac1 activity assay. *po0.05 between indicated group.
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speciﬁcally investigate the impact of protein S-glutathionylation
induction on the activation status of RhoA and Rac1, oxidized GSH
(GSSG) was utilized to induce protein S-glutathionylation via thiol-
disulﬁde bond exchange. The activity of RhoA and Rac1 was as-
sessed in, i) HAEC lysate incubated with GSSG; ii) HAECs exposed
to diamide, which is a well-established thiol-oxidizing agent andshown to increase intracellular GSSG. As shown in Fig. 4C and D,
both GSSG and diamide treatments inhibited Rac1 activity, de-
monstrating a negative regulatory effect of protein S-glutathio-
nylation on Rac1 activity in endothelial cells. In contrast with
HPHG treatment, RhoA activity was not increased by either GSSG
or diamide, suggesting a negligible effect of glutathionylation on
RhoA activity in endothelial cells. Focusing therefore on Rac1, we
Fig. 5. Pharmacological inhibition of Rac1 abolishes Glrx-1-mediated protection of EC barrier integrity against metabolic stress. HAECs were pre-incubated with or without
NSC-23766, a Rac1 speciﬁc inhibitor, at 100 μM for 30 mins. Cells were then exposed to vehicle (50 μM BSA, 5 mM glucose, 20 mMmannitol) or HPHG (200 μM palmitate-BSA
conjugate, 25 mM glucose) for additional 2 h. A–D: The effect of Glrx-1 on HPHG-induced formation of F-actin and disassembly of cell-cell adherens junctions is abrogated by
NSC-23766. Pre-incubation of HAECs with NSC-23766 induced the formation of F-actin (A and B) and delocalization of VE-Cadherin away from cell adherens junctions (C and
D) under both basal and HPHG challenge conditions. Scale bar¼25 mm. White arrows indicate intercellular gaps. Data are represented as mean7SEM. *po0.05, between
indicated groups. E: The effect of Glrx-1 on HPHG-induced permeability is abolished by NSC-23766. HAEC monolayers cultured onto Transwell inserts were pre-incubated
with NSC-23766 at 100 μM for 30 mins. Cells were then exposed to vehicle (50 μM BSA, 5 mM glucose, 20 mM mannitol) or HPHG (200 μM palmitate-BSA conjugate, 25 mM
glucose) for additional 2 h, followed by FITC-dextran inﬂux assay. Values are the normalized percentages of total FITC-dextran passing across monolayers about the control
group. Results represent Mean7SD of three independent experiments, each performed in triplicates. *po0.05, between indicated groups.
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Fig. 6. Cysteine mutants (C81S and C157S) of Rac1 resist S-glutathionylation and inactivation caused by metabolic stress. A–B: HPHG-induced oxidation of cysteine thiols of
Rac1 is inhibited by overexpression of Glrx-1. HAECs overexpressing LacZ (control) or hGlrx-1 were exposed to vehicle (50 μM BSA, 5 mM glucose, and 20 mM mannitol) or
HPHG (200 μM palmitate-BSA conjugate and 25 mM glucose) for 2 h. Cells were then lysed with RIPA buffer containing 10 mM NEM and subject to Biotin-switch assay. A:
Immunoblotting of reversibly oxidized Rac1 and β-actin from biotinylated proteins pulled down by streptavidin magnetic beads (upper panel), and Rac1 and β-actin from 10%
of total cell lysates, serving as loading controls (lower panel). B: Bar graph showing the fold changes in oxidized Rac1 (ratio of Biotinylated over total Rac1) relative to the
vehicle group from three independent experiments. * po0.05, compared between indicated groups. C–D: Mutation of cysteine residue 18, 81, or 157 to serine renders Rac1
resistant to HPHG-induced glutathionylation. Rac1 knock-out COS-7 cells generated by the CRISPR-Cas9 systemwere transiently transfected with GFP-Rac1 WT and indicated
cysteine mutants for 24 h. Cells were then loaded with 500 μM BioGEE for 1 h before challenges with vehicle (100 μM BSA, 5 mM Glucose, 20 mM mannitol) or HPHG
(400 μM palmitate-BSA conjugate and 25 mM glucose) for another 2 h. BioGEE labeled proteins pulled down with streptavidin magnetic beads were stained with MemCode
protein staining kit (A, upper panel), and underwent immunoblotting for Rac1 and β-actin (as a positive control). B: Bar graph showing the fold changes in glutathionylated
Rac1 (ratio of biotinylated over total input Rac1) relative to the vehicle group from three independent experiments.*po0.05 compared between indicated groups. E and F:
cysteine mutants (C18S and C157S) of Rac1 were resistant to HPHG-induced inactivation of Rac1. Rac1 knock-out COS-7 cells expressing GFP-Rac1 WT and indicated mutants
were subject to Rac1 pull-down activation assay. Values were the fold changes in the active form of Rac1 (ratio of GTP-bound form over total input Rac1) about to the vehicle
group from four independent experiments. *po0.05 compared between indicated groups.
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J. Han et al. / Redox Biology 9 (2016) 306–319316found that overexpression of Glrx-1 in HAECs prevented in-
activation of Rac1 caused by HPHG challenge (Fig. 4E and F).
3.5. Pharmacological inhibition of Rac1 abrogates the ability of Glrx-
1 to protect against endothelial barrier dysfunction in response to
metabolic stress in vitro
To examine whether Rac1 is involved in the effect of Glrx-1 on
EC barrier function, a speciﬁc inhibitor of Rac1 activation
(NSC23766), which interferes with the interaction between Rac1
and the Rac1-speciﬁc guanine nucleotide exchange factors (GEFs:
Trio and Tiam1) was employed. Pretreatment of HAEC with
100 μM NSC23766 increased the formation of stress ﬁbers in both
vehicle and HPHG-treated cells (Fig. 5A). Inhibition of Rac1 activity
also abrogated Glrx-1-mediated preservation of cell-cell junctions
(Fig. 5B). In concert with the effects on cytoskeletal organization
and cell-cell junctional integrity, Rac1 inactivation mitigated Glrx-
1-mediated protection of endothelial permeability against HPHG
(Fig. 5C). This set of data reafﬁrms the critical role of Rac1 in re-
dox-regulation of EC permeability. In support of this notion, HAECs
expressing green ﬂuorescence protein (GFP) tagged constitutively
active forms of Rac1 (Rac1CA), but not wild-type (Rac1WT), ex-
hibited an increase in cortical actin rim structure and resisted
against HPHG-induced cytoskeletal reorganization (supplemental
Fig. 3).
3.6. Glutathionylation of Rac1 on Cysteine 81 and 157 is responsibleFig. 7. The proposed redox mechanism for vascular barrier dysfunction associated
with metabolic disorders. Metabolic abnormalities including hyperglycemia, toxic
free fatty acids, and hypercholesterolemia, impair endothelial cell barrier function,
an early characteristic of vascular dysfunction associated with metabolic diseases.
In endothelial cells undergoing metabolic stress, the level of glutathionylated
proteins is elevated. Glutathionylation of Rac1 on Cys81 and Cys157 reduces the
activity of Rac1, resulting in loss of cortical actin structure, increased stress ﬁbers,
and disassembly of cell-cell adherens junctions. Inactivation of Rac1 increases actin
stress ﬁbers likely through release of its suppression on RhoA activation, a key
driver of stress ﬁber formation and actomyosin-based cell contractility. Over-
expression of Glrx-1 removes GSH adducts from Rac1 and restores its activity,
which in turn improves endothelial barrier dysfunction under conditions of me-
tabolic stress.for Rac1 inactivation caused by metabolic stress
Data from the biotin switch assay of HAECs demonstrated that
HPHG treatment promoted the reversible oxidations of Rac1 and
β-actin (serving as a positive control), which were effectively re-
versed by up-regulation of Glrx-1, suggesting that Rac1 is glu-
tathionylated in metabolically stressed endothelial cells (Fig. 6A
and B). To further investigate the mechanism of glutathionylation-
induced Rac1 inactivation, we sought to determine the speciﬁc
cysteine residues modiﬁed. As Cys18, Cys81, and Cys157 of Rac1 are
located adjacent to the guanine nucleotide binding site, and their
thiol oxidations are reported to be associated with the alteration of
GTPase activity status [39–41], we generated GFP-tagged Rac1
mutants in which Cys18, Cys81, or Cy157 was mutated to oxidation
resistant serine, and expressed them into a COS-7 cell line deﬁ-
cient in endogenous Rac1 using CRISPR-Cas9 system (Supple-
mental Fig. 4), allowing to assess the importance of these residues
on the redox regulation of Rac1. We determined the level of glu-
tathionylated Rac1 WT and cysteine oxidation resistant mutants in
Rac1 knockout COS-7 cells, which were loaded with cell-perme-
able BioGEE and then treated with HPHG. In comparison with
Rac1WT, HPHG-induced glutathionylation of Rac1C18S, Rac1C81S, or
Rac1C157S was signiﬁcantly decreased (Fig. 6C and D), suggesting
that all of these cysteine residues can undergo glutathionylation.
We further examined the impact of these modiﬁed cysteine re-
sidues on the Rac1 activity using PAK pull-down assay. As shown
in Fig. 6E and F, the activity of Rac1C18S was inhibited by HPHG
treatment to the extent similar as that of Rac1WT, whereas Rac1
C81S and Rac1C157S resisted against the decrease in activity. Col-
lectively, these results suggest a causative role of glutathionylation
of Rac1, especially on Cys81 and Cys157, in metabolic stress-induced
Rac1 inactivation and consequent impairment of barrier function.4. DISCUSSION
The novel ﬁndings of the present study include the following:
1) in endothelial cells under conditions of diabetes and hyperch-
olesterolemia, the levels of protein S-glutathionylation are ele-
vated; 2) removing protein S-glutathionylation by overexpressing
Glrx-1 protects against vascular barrier dysfunction in hypercho-
lesterolemic mice; 3) glutathionylation of Rac1 on cysteine residue
81 and 157 is associated with the defect in Rac1 activation status,
representing an important redox mechanism for metabolic stress-
induced endothelial cell barrier failure (Fig. 7).
Protein S-glutathionylation is generally associated with in-
creased oxidative or nitrosative stress during such pathological
conditions as ischemia-reperfusion and hypertension [42,43],
regulating cardiovascular responses to stress and injury. Sustained
overproduction of ROS has emerged as a common element in a
variety of mechanisms controlling vascular complications of me-
tabolic disorders [44], but how protein S-glutathionylation in en-
dothelial cells is involved in these pathogenic processes has not
been investigated. In the present study, we show that glutathio-
nylated proteins are markedly increased in endothelial cells under
conditions of diabetes and hyperlipidemia (Fig. 1). This elevated
thiol oxidation plays a causative role in metabolic stress-induced
aortic barrier dysfunction through altering cytoskeletal organiza-
tion and cell-cell adhesion integrity (Figs. 2 and 3). In particular, at
the atherosclerotic lesion-prone aortic arch segment, vascular
permeability is increased and can be attenuated by overexpressing
Glrx-1 in hypercholesteremic mice. As endothelial hyperperme-
ability is an important initiating factor in atherogenesis by in-
creasing lipoprotein entry and favoring leukocyte transmigration
into the arterial wall [14–16,45,46]. we speculate that protein
S-glutathionylation in endothelial cells may participate in
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Endothelial barrier integrity is a key manifestation of en-
dothelial function and tightly associated with cellular redox status
[47], but the underlying mechanism is not completely deﬁned. In
particular, little is known about the role of protein S-glutathio-
nylation in redox regulation of endothelial permeability, although
it has been reported that the ratio of reduced to oxidized GSH is
essential for maintenance of endothelial cell barrier function [18].
The novel ﬁnding in the present study is the role of protein
S-glutathionylation in cytoskeletal reorganization in response to
metabolic stress, resulting in increased permeability (Figs. 2–5). β-
actin is one of the earliest identiﬁed cytoskeletal protein suscep-
tible to glutathionylation. Glrx-1-mediated removal of GSH from
β-actin leads to a 6-fold increase in the rate of polymerization
[48,49]. Consistently, our results showed that in endothelial cells,
Glrx-1 reversed glutathionylation of β-actin with a concomitant
increase in F-actin content under basal condition. Metabolic stress
imposed by high levels of palmitate and glucose increased glu-
tathionylation of β-actin and stimulated stress ﬁber formation,
which is very unlikely mediated by glutathionylation of β-actin
itself. Overexpression of Glrx-1 resisted against metabolic stress-
induced stress ﬁber formation (Figs. 2 and 4). We further showed
that glutathionylation of Rac1 on Cys81 and Cys157, but not RhoA,
is involved in redox-regulated cytoskeleton reorganization and
permeability (Figs. 5 and 6). Consistently, a defect in Rac1-medi-
ated cortical actin structure, but not in RhoA/ROCK signaling, was
recently shown to drive endothelial barrier failure in response to
hypoxia/reoxygenation [50], which is known to increase protein
S-glutathionylation [26,51]. The impaired Rac1/cytoskeleton sig-
naling was also linked to insulin and glucose intolerance in obesity
and diabetes [52–54]. The present study provides a novel redox
mechanism linking Rac1 inactivation to vascular barrier impair-
ment caused by metabolic stress. Herein, Rac1 activity is accessed
by measuring the level of association with PAK1, which is a major
downstream effector conveying the role of Rac1 in actin cytoske-
leton reorganization and endothelial barrier integrity enhance-
ment [55], our data thus do not provide information about the
impact of glutathionylation on the interactions of Rac1 with other
downstream effectors such as p67, a component of NADPH oxidase
[56], neither on the guanine nucleotide exchange and GTP hy-
drolysis [22]. A recent study reported that glutathionylation of
Rac1 on Cys18 contributes to oxidant-induced activation by pro-
moting guanine nucleotide exchange [39]. In line with this ﬁnding,
our results suggest that glutathionylation of Cys18 is not required
for metabolic stress-induced Rac1 inactivation, and may counter-
act the inhibitory effect on Rac1 activity exerted by modiﬁcation of
Cys81 and Cys157. It is also appreciated that Rac1, as a con-
vergence point for multiple signaling pathways involving en-
dothelial barrier enhancement, and can be activated by such sig-
naling cascades as PKA/cAMP and PI3K/Akt [57,58]. Both PKA and
Akt can be modulated by S-glutathionylation [59,60]. It is also
possible that the observed change in Rac1 activity is a net effect of
multiple glutathionylation-mediated signaling events. The de-
tailed mechanisms warrant further investigations. Because Rac1
also supports NADPH-oxidase-mediated ROS generation via
translocating to membrane and facilitating the assembly Nox
subunits, it is likely to contribute to oxidative stress-induced
vascular pathology and proposed as a therapeutic target for car-
diovascular diseases [38]. This present study together with other
reports demonstrates an essential role of Rac1 in vascular and
metabolic hemostasis. It necessitates a better understanding of
stimulus-speciﬁc regulation of Rac1 activation status and precise
mechanisms how Rac1 is involved in cardiovascular pathologies,
which may lead to highly selective therapeutic targeting.
Here, we chose to induce metabolic stress to endothelial cells in
vitro using combined treatment with high glucose and highpalmitate, which mimic elevated circulating glucose and free fatty
acids (FFA) in patients with type 2 diabetes mellitus [61]. It has
been well documented that this in vitro treatment induces en-
dothelial cell dysfunction, including impaired eNOS signaling,
apoptosis, inﬂammation and autophagy [32–35,62]. Of note, plas-
ma levels of FFA and glucose in patients are positively correlated
with the severity of diabetes mellitus, ranging from 200 to 800 μM
for FFA, from 130 to 400 mg/dL for glucose [63]. In ApoE-/- mice, a
mouse model of hypercholesterolemia used in the present study,
the FFA concentration is elevated after two weeks on the Western
diet (200 μM). These mice display increased fasting glucose levels
on a normal diet (146 mg/dL) and the Western diet (155 mg/dL),
which is consistent with a recent report [64] (Supplemental Ta-
ble 1). Based on this information and experimental literature [32–
35,62], we treated endothelial cells with high glucose (450 mg/dL)
together with palmitate at concentrations ranging from 50 to
300 μM. We are aware of that this in vitro model does not com-
pletely recapitulate metabolic stress imposed on vascular en-
dothelium under diabetic conditions in vivo, although our studies
focus on the role of protein glutathionylation in redox regulation
of endothelial barrier function, and the combined treatment suc-
cessfully induces glutathionylation of endothelial proteins, in
particular Rac1, and barrier integrity failure, allowing us to in-
vestigate their causal relationship. Oxidative stress appears to be a
major mechanism mediating metabolic stress-induced endothelial
dysfunction [31]. High levels of glucose or palmitate alone are
reported to stimulate intracellular ROS generation and may con-
tribute to the increased protein S-glutathionylation in endothelial
cells. We tested this possibility (Supplemental Fig. 5) and found
that high palmitate, but not high glucose, stimulated protein
S-glutathionylation. Interestingly, the combined treatment exerted
a synergic effect, possibly due to an additive increase in ROS
generation, particularly derived from mitochondria, whose func-
tion is severely impaired by this combination treatment [65].
Our in vivo ﬁndings on Glrx-1 TG mice do not distinguish
possible effects of downregulation of protein S-glutathionylation
in cell types other than ECs that may have inﬂuenced aortic per-
meability. However, our in vitro experiments with overexpression
of Glrx-1 in aortic endothelial cells showed strong parallels with
the in vivo ﬁndings that include stabilized actin cytoskeletal
structures and preserved barrier integrity.
In summary, we have demonstrated that S-glutathionylation, a
reversible oxidative modiﬁcation of proteins, is elevated in en-
dothelial cells under conditions of diabetes and hyperlipidemia,
contributing to metabolic stress-induced endothelial barrier fail-
ure. Glutathionylation of Rac1 on cysteine residue 81 and 157
appears as an important redox mechanism controlling endothelial
cell barrier function in response to metabolic abnormalities.Sources of funding
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